Search Menu
Photonics Media Photonics Marketplace Photonics Spectra BioPhotonics Vision Spectra Photonics Showcase Photonics ProdSpec Photonics Handbook

Fosun Pharma Acquires Alma Lasers

Facebook Twitter LinkedIn Email
HONG KONG, April 29, 2013 — Health care company Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is acquiring a 95.6 percent stake in Israel-based Alma Lasers Ltd. for $240 million, the company announced Sunday.

Alma Lasers was formed in October 2005 from the merger of US-based Orion lasers and Israel-based MSQ. Alma Lasers makes laser, light-based, radio-frequency and ultrasound products for aesthetic and medical applications. Its research and development facilities are in Caesarea, Israel, and its global support center is in Chicago.

Alma Lasers entered the Chinese market in 2003 and now has a 15 percent market share in the global high-end medical and beauty laser products industry with annual revenue of $100 million, the company said, adding that China is by far one of the biggest markets for Alma Lasers.

"We are confident in the growth of the global aesthetics industry, especially in China, Brazil, Russia and India," said Fosun Pharma Chairman Chen Qiyu. "This represents a huge development space in developing countries."

Hong Kong-based Fosun Pharma, which is making the acquisition with its subsidiary, Pramerica-Fosun Fund, said it will use Alma Lasers as a management platform for the R&D, manufacturing and sales of high-end medical devices, providing the company with an internationalized development path.

For more information, visit: or
Apr 2013
acquisitionsaesthetic laserAlma LasersAmericasAsia-PacificBiophotonicsBusinessChicagoChinaFosun PharmaHong KongindustrialIsraelmedical laserMiddle EastMSQOrion lasersPramerica-Fosun Fundtransactionlasersmergers & acquisitions

back to top
Facebook Twitter Instagram LinkedIn YouTube RSS
©2023 Photonics Media, 100 West St., Pittsfield, MA, 01201 USA, [email protected]

Photonics Media, Laurin Publishing
x We deliver – right to your inbox. Subscribe FREE to our newsletters.
We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.